Bente Vilming Elgaaen

  • Associate member MD PhD
MiRNA analyses in ovarian cancers
 

Author network for Bente Vilming Elgaaen by COREMINE medical


Publications 2016

Tambe M, Pruikkonen S, Mäki-Jouppila J, Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE, Davidson B, Hautaniemi S, Kallio MJ (2016)
Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel
Oncotarget, 7 (11), 12267-85
DOI 10.18632/oncotarget.7860, PubMed 26943585

Publications 2014

Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, Reich R, Falkenthal TE (2014)
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
Virchows Arch, 464 (6), 701-7
DOI 10.1007/s00428-014-1577-7, PubMed 24756216

Publications 2012

Elgaaen BV, Olstad OK, Sandvik L, Odegaard E, Sauer T, Staff AC, Gautvik KM (2012)
ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival
PLoS One, 7 (9), e46317
DOI 10.1371/journal.pone.0046317, PubMed 23029477

Publications 2010

Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, Staff AC, Sauer T, Gautvik KM (2010)
POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas
PLoS One, 5 (11), e13837
DOI 10.1371/journal.pone.0013837, PubMed 21079801

Publications 2008

Ødegaard E, Davidson B, Elgaaen BV, Fagerhol MK, Engh V, Onsrud M, Staff AC (2008)
Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary
Am J Obstet Gynecol, 198 (4), 418.e1-7
DOI 10.1016/j.ajog.2007.10.792, PubMed 18241816

Page visits: 2123